Literature DB >> 34551091

The Impact of Prior Infection and Age on Antibody Persistence After Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine.

Elizabeth Fraley1, Cas LeMaster1, Santosh Khanal1, Dithi Banerjee1, Tomi Pastinen1, Elin Grundberg1, Rangaraj Selvarangan1, Todd Bradley1.   

Abstract

Determining the duration of immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is critical for informing the timing of booster immunization. Many genetic and environmental factors could influence both the magnitude and persistence of the antibody response. Here, we showed that SARS-CoV-2 infection before vaccination and age affected the decay of antibody responses to the SARS-CoV-2 messenger RNA vaccine.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  19; 2; Antibody response; COVID; CoV; SARS; Vaccine

Mesh:

Substances:

Year:  2022        PMID: 34551091      PMCID: PMC8522412          DOI: 10.1093/cid/ciab850

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   20.999


  4 in total

1.  SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection.

Authors:  A Sarah Walker; David W Eyre; Koen B Pouwels; Jia Wei; Philippa C Matthews; Nicole Stoesser; Ian Diamond; Ruth Studley; Emma Rourke; Duncan Cook; John I Bell; John N Newton; Jeremy Farrar; Alison Howarth; Brian D Marsden; Sarah Hoosdally; E Yvonne Jones; David I Stuart; Derrick W Crook; Tim E A Peto
Journal:  Nat Commun       Date:  2022-06-29       Impact factor: 17.694

2.  Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases.

Authors:  Athanasios-Dimitrios Bakasis; Kleopatra Bitzogli; Dimitrios Mouziouras; Abraham Pouliakis; Maria Roumpoutsou; Andreas V Goules; Theodoros Androutsakos
Journal:  Viruses       Date:  2022-01-21       Impact factor: 5.048

3.  Effectiveness of mRNA-1273, BNT162b2, and JNJ-78436735 COVID-19 Vaccines Among US Military Personnel Before and During the Predominance of the Delta Variant.

Authors:  Angelia A Eick-Cost; Saixia Ying; Natalie Wells
Journal:  JAMA Netw Open       Date:  2022-04-01

4.  Investigation of Possible Factors Influencing the Neutralizing Anti-SARS-CoV-2 Antibody Titer after Six Months from the Second Vaccination Dose in a Sample of Italian Nursing Home Personnel.

Authors:  Alberto Modenese; Stefania Paduano; Rossana Bellucci; Simona Marchetti; Fulvio Bruno; Pietro Grazioli; Roberto Vivoli; Fabriziomaria Gobba; Annalisa Bargellini
Journal:  Antibodies (Basel)       Date:  2022-09-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.